Sauer R, Liersch T, Merkel S et al. 


Gérard JP, Conroy T, Bonnetain F et al. The TME trial after a median follow-up of 11years. ASCO Annual Meeting, abstract 80285 2011


Hillner BE, Siegel BA, Shields AF et al. Randomized trial. Lancet 2009; 373: 811


Sprenger T, Rothe H, Jung K et al. Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: do we have indications for individual risk stratification? World J Surg Oncol 2010; 8: 27


Habr-Gama A. Assessment and management of the complete clinical response of rectal cancer to chemoradiotherapy. Colorectal Dis 2006; 8 (Suppl. 03): 21–24


97 Gaedcke J, Grade M, Jung K et al. KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. Radiother Oncol 2010; 94: 76–81
105 Quah HM, Chou JF, Gonen M et al. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer 2008; 113: 57–64